- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05982769
Mecanismo molecular del ejercicio en la cirrosis
This study aims to investigate the effects of 12 weeks of resistance or endurance exercise on patients with cirrhosis. Cirrhotic patients are prone to muscle loss (sarcopenia) and ammonia build up due to liver dysfunction. The liver which in healthy patients is able to process ammonia through ureagenesis is unable to do so in cirrhosis and ammonia is taken up either by the brain causing confusion or the skeletal muscle causing muscle loss or sarcopenia. Primary sarcopenia occurs in older individuals and can be mitigated by exercise. Secondary sarcopenia occurs in response to disease such as cancer, chronic kidney disease, multiple sclerosis, and cirrhosis of all etiologies. Resistance exercise is an excellent stimulator for muscle protein synthesis and is widely used to build muscle mass and strength but has little benefit to cardiovascular function. Endurance exercise has shown to be safe in cirrhosis however there is no set prescription for cirrhosis as there is for other disease. Endurance exercise is known to promote improved cardiovascular health, improve fatigue, and generates less ammonia build up than resistance exercise. In patients with low muscle mass it is possible that endurance exercise alone will be enough to improve muscle mass. There have been few studies on exercise and cirrhosis, those that exist have shown benefits with endurance exercise. However there are even more limited studies on resistance exercise and few to no studies on the molecular mechanisms behind exercise in cirrhosis. Study visits are described fully in the protocol and consent form. After passing a screening visit patients will undergo a maximal exercise/fitness test (pre-baseline test) and other body composition measurements. After the screening and pre-baseline visit randomization will occur (2:2:1 endurance, resistance, or SOC) arrangements will be made to have the appropriate exercise equipment given to patients. Once the exercise equipment has arrived a baseline study visit will occur. After the baseline visit the endurance exercise group will cycle 3 days per week for 60 minutes under the supervision of the study team. The resistance exercise group will perform a whole body resistance workout 2 days per week for approximately 60 minutes under the supervision of a study team member.
Patients in all groups will have the fitness test repeated at weeks 4, 8 and 12. After the 12 weeks of exercise the baseline visits will be repeated and after 2 weeks patients will complete one final fitness test to examine the effects of de-training.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Srinivasan Dasarathy, MD
- Número de teléfono: 216-318-7010
- Correo electrónico: dasaras@ccf.org
Copia de seguridad de contactos de estudio
- Nombre: Annette Bellar
- Correo electrónico: bellara@ccf.org
Ubicaciones de estudio
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Reclutamiento
- Cleveland Clinic
-
Contacto:
- Annette Bellar
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion
- Adult patients age 21-65 years of both genders
- Diagnosis of cirrhosis by either liver biopsy, clinical, biochemical or imaging criteria
- Child's score 5-10
- Model for End Stage Liver Disease (MELD) score less than 21
- Abstinence from alcohol and/or other recreational drugs for at least 6 months
- Absence of concurrent illnesses (renal, cardiac, pulmonary, cerebrovascular, malignancy) or medication (anabolic steroids, corticosteroids) intake that affect skeletal muscle mass, diabetes mellitus (avoid altered muscle protein metabolism), or use of anticoagulants.
- abdominal or liver CT scan within 1 year of enrollment for stratification Exclusion
- Active alcohol consumption within 6 weeks of enrollment
- Pedal edema (grade 2) above the ankle will be excluded to avoid complications of the muscle biopsy.
- Liver transplant
- Active Malignancy
- Recent GI bleed (4 weeks)
- Hepatic Encephalopathy within previous 6 months
- Grade 2 or greater active esophageal varices
- Active infection
- Large Ascites as defined by clinical imaging
- Advanced disease cardiac or pulmonary disease
- Use of medications affecting muscle protein turnover including corticosteroids or medications used to prevent clotting
- Clinical lab values that indicate potential poor clotting as determined by the PI
- Inability to obtain informed consent; judged likely to be unable to perform exercise or unlikely to complete the study in the opinion of the investigators
- End stage kidney disease as determined by glomerular filtration rate (eGFR) < 15 ml/min/1.73m2 or dialysis
- Patients who in the opinion of the PI are unsafe for exercise (failure to pass stress test)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Estándar de cuidado
|
continue usual activity |
|
Experimental: Brazo de resistencia
|
endurance training will be performed from home 3 times per week under the supervision of the research team. |
|
Experimental: Resistencia
|
resistance training will be performed from home 2 times per week under the supervision of the research team. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Cambio en la masa muscular con el tiempo
Periodo de tiempo: día 0 y día 90
|
día 0 y día 90
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades del Sistema Digestivo
- Enfermedades del HIGADO
- Fibrosis
- Condiciones Patológicas, Signos y Síntomas
- Cirrosis hepática
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Actividad motora
- Movimiento
- Fenómenos fisiológicos musculoesqueléticos
- Fenómenos fisiológicos musculoesqueléticos y neuronales
- Terapéutica
- Calidad de la atención médica
- Modalidades de fisioterapia
- Indicadores de calidad, atención médica
- Atención al paciente
- Terapia de ejercicio
- Rehabilitación
- Cuidado por los convalecientes
- Continuidad de la atención al paciente
- Acondicionamiento físico, humano
- Ejercicio
- Estándar de cuidado
- Entrenamiento de resistencia
Otros números de identificación del estudio
- 21-090
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .